FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to pharmaceutical combination comprising: (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)pyridin-4-yl]thiazol-2-yl}amide) or a pharmaceutically acceptable salt thereof, and at least one aromatase inhibitor selected from letrozole or exemestane, or pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use in treatment of cancer; as well as to applying combination for treatment of cancer; to method of treating cancer; to set and synergistic combination.
EFFECT: group of inventions provides synergistic effect in treatment of cancer.
10 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY FOR CANCER TREATMENT | 2014 |
|
RU2805145C2 |
| COMBINATION THERAPY FOR TREATMENT OF CANCER | 2014 |
|
RU2680714C2 |
| 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2624493C2 |
| COMBINATION OF PIK3 INHIBITOR AND INHIBITOR C-MET | 2013 |
|
RU2705095C2 |
| COMPOUNDS WHICH ARE ERK INHIBITORS | 2009 |
|
RU2525389C2 |
| USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS | 2011 |
|
RU2589695C2 |
| COMBINATIONS INCLUDING EPOTHILONES AND THEIR PHARMACEUTICAL APPLICATION | 2003 |
|
RU2379032C9 |
| COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
| METHOD AND SET FOR TREATING AND PREVENTING MALIGNANT TUMOURS OF FEMALE REPRODUCTIVE SYSTEM USING 9-OXOACRIDINE-10-ACETIC ACID, AND/OR SALT THEREOF AND/OR ESTER THEREOF | 2007 |
|
RU2363466C2 |
